The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies

ObjectiveThe efficacy of regorafenib or fruquintinib in combination with PD-1/PD-L1 inhibitors for metastatic colorectal cancer (mCRC) treatment has not been elucidated. This study aims to systematically evaluate the efficacy and safety of this combination therapy.MethodsPubMed, Embase, Cochrane Lib...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fan Yang, Ying Mao, Hanyu Huang, Wen Luo, Li Liu, Wenzhi Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-05-01
Edice:	Frontiers in Immunology
Témata:	metastatic colorectal cancer regorafenib fruquintinib PD-1/PD-L1 inhibitors meta-analysis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579293/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!